Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006 - Wikidata - wikimedia - TriplyDB

Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006

Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006

http://www.wikidata.org/entity/Q33723583

about

Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality?Factors associated with mortality in transplant patients with invasive aspergillosis Breakthrough Hormographiella aspergillata infections arising in neutropenic patients treated empirically with caspofungin.Outcome of adult acute lymphoblastic leukemia in South East of iran (zahedan).High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan.Antifungal management and resource use in patients with acute myeloid leukaemia after chemotherapy--retrospective analysis of changes over 3 yr in a German hospital.Invasive fungal infections in acute leukemia.Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species.Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy.Infection prevention in the cancer center.Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain.Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country.Outcome of empirical or targeted antifungal therapy after antifungal prophylaxis in febrile neutropenia.How can we help haematological cancer survivors cope with the changes they experience as a result of their cancer?Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China Use of intravoxel incoherent motion diffusion-weighted MR imaging for assessment of treatment response to invasive fungal infection in the lung.Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.Predicting early post-chemotherapy adverse events in patients with hematological malignancies: a retrospective study.Unmasking fungal pathogens by studying MAPK-dependent cell wall regulation in Candida albicans.The serum glucan level and pathological changes of antifungal treatment for lower respiratory tract infection of Candida albicans.Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China.Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.Folate fortification and survival of children with acute lymphoblastic leukemia.Incidence and outcomes of invasive fungal disease in adult patients with acute lymphoblastic leukemia treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone: implications for prophylaxis.Alkylated Piperazines and Piperazine-Azole Hybrids as Antifungal Agents.Neutropenia and invasive fungal infection in patients with hematological malignancies treated with chemotherapy: a multicenter, prospective, non-interventional study in China

P2860

Q30240242-E43CC88D-9330-4309-A650-9748D3FDE854 Q33867013-DB1C2056-A033-4156-8EDA-0F7BDC8C5FC8 Q34487440-DD22883B-8B1C-4611-8D62-B9CA6F58F8B4 Q34959054-0D332128-5670-4AD6-8D71-C8A04E2AC34F Q35659664-4B262D9C-D14B-4E41-A45F-A10D29202C42 Q35700698-DFB34902-AA25-437C-89C8-7BCB682C53BF Q36612597-35D861C1-E959-40BC-ACFA-9F48E25327E6 Q37480190-423650FA-7842-4A22-8EF6-9AD754057752 Q37701894-D898A001-E0F4-4385-892B-0C138ECBE68D Q37900678-B507D8B4-5929-42F1-B34B-D8894ABDFB24 Q38104929-87E1B16F-0BA6-4649-9BAE-02D80901FC9A Q38624599-BE883DFB-99B8-4F0E-89D0-F8299E4ED8A0 Q38665409-3AE61C89-CCD3-4B3F-836B-705A8D359CBA Q39883914-870929E7-903D-45CA-B5D8-0E3D7368D22D Q40469129-4573852A-3CFE-4137-BF44-CC82585CA914 Q40629298-59AB95A6-D6E2-4BA9-A42F-EAD77DA88C94 Q40674435-D3C029BE-B0EE-499B-BEB5-58A66A70A0EC Q40691888-315FCF55-CD95-4239-BB8B-D60CF89460C3 Q40820446-27CD90E9-3362-4243-AF85-687B9183ED9A Q41113383-FF45D0E3-9C09-401B-8315-E36FD7C3705D Q41570426-61C2B86A-06C3-4EB0-92A9-A7A2DC88E1CA Q41712164-F4862C64-DAD9-463E-90EA-EBD6B22CA692 Q44482692-FCA77DFE-3585-43FD-B882-0F674509B3E5 Q45156191-5573FA03-F610-404E-802C-178F5CD11DB5 Q45735890-FA0BB039-CFA8-46FC-96FC-A0E297CBD111 Q48095380-73DE2DF2-73C7-4056-8A7C-F31E3919455F Q56518068-9CC63824-FA6F-40F3-A5BF-2386C80AA864

P2860

Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006

http://www.wikidata.org/entity/Q33723583

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Overall survival and fungal in ...... care centre from 1995 to 2006

@ast

Overall survival and fungal in ...... care centre from 1995 to 2006

@en

type

label

Overall survival and fungal in ...... care centre from 1995 to 2006

@ast

Overall survival and fungal in ...... care centre from 1995 to 2006

@en

prefLabel

Overall survival and fungal in ...... care centre from 1995 to 2006

@ast

Overall survival and fungal in ...... care centre from 1995 to 2006

@en

P1433

Q33723583-57ED6DB3-072B-4982-9D40-BC56B398FE25

P1476

Q33723583-62DF48B8-367B-48D8-8D76-33CE03A99FDD

P2093

Q33723583-13796DEE-A23D-494C-8501-42C259FBA482

Q33723583-2C9FFE9C-47D9-4561-B225-28AAD2BA3A1F

Q33723583-8B8937CE-3495-491E-908F-4889D7FD6CD7

Q33723583-C5C73318-2349-47A4-A74F-135D2FBB83BD

Q33723583-C9532ACF-9A06-44D8-A44E-7671B0640E47

Q33723583-D7C219D6-8772-46B0-B032-0F0FC661A024

Q33723583-EE679791-289F-4D85-8447-5795CBB9E3B8

Q33723583-EE9FC742-4970-40E9-BEC1-7B5AD96F3FA8

P2860

Q33723583-04EA6DAE-D78B-4F93-8F60-BE3A90AEAB4E

Q33723583-1C22A293-4107-485C-A311-E2999B69252F

Q33723583-20A45DBC-4F39-42D1-B646-07FFD81E3E13

Q33723583-2F0BFDA3-6107-47F2-BE22-A4B47D6EA4B4

Q33723583-4B661524-49EF-47B3-B017-6AF1C011A6FB

Q33723583-4B72F630-5444-4F4D-B3B7-0183E1F3A9D0

Q33723583-545BB0E0-9B79-4779-9DAE-2A2B97CB13FF

Q33723583-61F6097A-D980-465D-A28D-C12E7E98C68A

Q33723583-6B9E55C7-BBB9-4D1B-83FD-524DFA87F97A

Q33723583-6CBA406B-C748-4502-89ED-E01E2402C005

P304

Q33723583-BD4D2716-80D1-4ED6-9F0C-95C6C2B1B2FF

P31

Q33723583-878A0881-CD71-448B-B153-99B49CE84D64

P356

Q33723583-256DFE86-6B9B-4338-89B0-A4B15BCEF758

P407

Q33723583-4C02EAB3-D495-49E7-BABE-2BE7DDB4B800

P433

Q33723583-552B5A6E-3D79-46C4-B444-87C97EA26A22

P478

Q33723583-E9993DAE-CACB-439C-A264-CD0C5624698B

P577

Q33723583-FA559BE8-4C80-4DAF-AEEE-0DA1BB047B7A

P5875

Q33723583-18B3B389-A084-4C4D-9723-E5EA91ACFCBA

P698

Q33723583-8DF44550-14D6-478B-993B-BCD990717C7B

P921

Q33723583-DB2FCE82-F25C-4BCE-B745-3423E65B07C0

P932

Q33723583-0894A21B-5046-4BCB-B6C7-5938F5FFEFAC

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Overall survival and fungal in ...... care centre from 1995 to 2006

@en

P2093

Andrea Schmitz

http://www.w3.org/2001/XMLSchema#string

Anja Kraemer

http://www.w3.org/2001/XMLSchema#string

Axel Glasmacher

http://www.w3.org/2001/XMLSchema#string

Corinna Hahn-Ast

http://www.w3.org/2001/XMLSchema#string

Günter Marklein

http://www.w3.org/2001/XMLSchema#string

Marie von Lilienfeld-Toal

http://www.w3.org/2001/XMLSchema#string

Peter Brossart

http://www.w3.org/2001/XMLSchema#string

Sara Mückter

http://www.w3.org/2001/XMLSchema#string

P2860

Systemic Fungal Infections Caused by Aspergillus Species: Epidemiology, Infection Process and Virulence Determinants

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Invasive fungal infections in hematology: new trends.

Empirical antifungal therapy in treating febrile neutropenic patients.

Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality.

Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

P304

761-768

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKP507

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41165876

http://www.w3.org/2001/XMLSchema#string

P698

20106864

http://www.w3.org/2001/XMLSchema#string

P921

P932

2837550

http://www.w3.org/2001/XMLSchema#string